Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103450 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
A Phase 3 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT04103450 is a Phase 3 study that has completed, run by Urovant Sciences. The registered enrollment target is 276 participants.
The verdict
NCT04103450, a Phase 3 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
Interventions
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04103450
The ClinicalTrials.gov registry entry for NCT04103450 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vibegron is the first listed.
NCT04103450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04103450 about?
NCT04103450 is a clinical study titled "Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia". This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
What is the current status of trial NCT04103450?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2019-09-19. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT04103450?
The interventions under investigation include: Vibegron (DRUG).
Who is sponsoring clinical trial NCT04103450?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.